Rosen Law Firm Encourages Intellia Therapeutics Investors to Act Before Deadline

NEW YORK, March 09, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds investors who purchased securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024, and January 8, 2025 (the "Class Period"), about the significant April 14, 2025 lead plaintiff deadline.

SO WHAT: If you acquired Intellia securities during the Class Period, you may have the right to seek compensation without any out-of-pocket expenses through a contingency fee arrangement.

WHAT TO DO NEXT: To participate in the Intellia class action, you can visit this link, or you may contact Phillip Kim, Esq. toll-free at 866-767-3653 or via email at [email protected] for more details regarding the class action. A class action lawsuit has already been initiated, and if you wish to take on the role of lead plaintiff, you need to file a motion with the court by April 14, 2025. The lead plaintiff serves as a representative for other class members in managing the litigation.

WHY ROSEN LAW: We advise investors to select experienced legal counsel with a proven track record in significant leadership roles. Many firms sending out notices do not possess the same level of experience, resources, or peer recognition. It is crucial to choose wisely, as some of these firms may act merely as intermediaries and refer clients to other law firms that conduct the litigation. The Rosen Law Firm represents investors globally, specializing in securities class actions and shareholder derivative litigation. The firm previously achieved the highest securities class action settlement against a Chinese company at that time and has been recognized consistently for its successful settlements, recovering hundreds of millions of dollars for investors.

DETAILS OF THE CASE: The lawsuit claims that during the Class Period, defendants provided investors with misleading information regarding Intellia’s Phase 1/2 study assessing NTLA-3001 for treating alpha-1 antitrypsin deficiency (AATD)-related lung disease. The defendants communicated confidence in the timeline for this study, stating that the first patient would be dosed in the latter half of 2024. However, they did not disclose important details about the declining demand for viral-based editing, as non-viral delivery methods became the leading focus of scientific research due to their efficiency and cost-effectiveness, rendering NTLA-3001 an ineffective program for Intellia to maintain. When the factual details became known, investors reportedly experienced financial losses.

For more information about joining the Intellia class action, please visit this link or reach out to Phillip Kim, Esq. toll-free at 866-767-3653 or via email at [email protected].

No class has yet been certified. Until a class is certified, individuals are not represented by counsel unless they retain one. Investors can choose their counsel or remain an absent class member and take no action at this time. Being a lead plaintiff does not affect an investor's right to participate in any potential recovery.

Stay updated by following on LinkedIn: here, on Twitter: here, or on Facebook: here.

Attorney Advertising. Past results do not guarantee a similar outcome.

For further inquiries, please contact:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll-Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

Intellia, Investors, ClassAction